Regulation of CCL18 by Corticosteroids in Severe Asthma

Inclusion criteria

• control subjects =

• non-atopic and non-smoking
• cutting to negative pneumoallergens,
• Total IgE levels less than 100 ku / L
• no clinical history of asthma
• without background treatment
• patients with intermittent asthma =

• being asymptomatic between asthma attacks,
• with symptoms less than once a week
• having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical.
• treated by ß2 mimetics on demand and will not have inhaled corticosteroids.
• severe asthma insensitive to corticosteroid therapy =

• continuous or nearly continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)] airway obstruction fixed with FEV1 ranging from less than 15% after 7 days of oral corticosteroid therapy to 40 mg / day of prednisolone;
• Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
• Severe corticosensitive asthma = continuous or near continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)]

• reversibility of FEV1 after treatment with oral corticosteroids.
• Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
• controlled moderate asthma treated with inhaled corticosteroids <1500μg equivalent of beclomethasone dipropionate and with: ß2 long-acting mimetics (or anti-leukotriene, or theophylline) for at least 6 months.

Exclusion criteria

• existence of a chronic inflammatory pathology other than asthma
• active smoking
• pregnant or lactating women
• have received oral corticosteroid treatment in the previous 3 weeks,
• have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks.